NCT06373601View on ClinicalTrials.gov

SPAGO: Sirolimus Paclitaxel Angiographic Gain Objective

NAActive, not recruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

September 5, 2024

Primary Completion Date

August 1, 2027

Study Completion Date

August 1, 2027

Conditions
Coronary Artery DiseaseStenosis CoronaryCoronary Artery LesionPercutaneous Coronary Intervention
Interventions
DEVICE

sirolimus-eluting balloon (Selution)

PCI treatment with DCB, in particular sirolimus coated balloon

DEVICE

paclitaxel-eluting balloon (SeQuent Please Neo)

PCI treatment with DCB, in particular paclitaxel coated balloon

Trial Locations (10)

10043

Azienda Ospedaliero Universitaria San Luigi Gonzaga, Orbassano

13100

Ospedale Sant'Andrea, Vercelli

20089

Istituto Clinico Humanitas, Rozzano

20138

Centro Cardiologico Monzino, Milan

24127

ASST Papa Giovanni XXIII, Bergamo

25124

Fondazione Poliambulanza, Brescia

44124

Azienda Ospedaliero Universitaria di Ferrara, Ferrara

80122

Clinica Mediterranea, Napoli

83013

Clinica Montevergine, Mercogliano

10098ù

Ospedale di Rivoli, Rivoli

All Listed Sponsors
lead

Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS

OTHER

NCT06373601 - SPAGO: Sirolimus Paclitaxel Angiographic Gain Objective | Biotech Hunter | Biotech Hunter